NZ542260A - Treatment of intestinal conditions with mecamylamine - Google Patents
Treatment of intestinal conditions with mecamylamineInfo
- Publication number
- NZ542260A NZ542260A NZ542260A NZ54226004A NZ542260A NZ 542260 A NZ542260 A NZ 542260A NZ 542260 A NZ542260 A NZ 542260A NZ 54226004 A NZ54226004 A NZ 54226004A NZ 542260 A NZ542260 A NZ 542260A
- Authority
- NZ
- New Zealand
- Prior art keywords
- gastrointestinal motility
- enriched
- neurogenic
- abnormal increase
- mecamylamine
- Prior art date
Links
- 230000000968 intestinal effect Effects 0.000 title 1
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 title 1
- 229960002525 mecamylamine Drugs 0.000 title 1
- 230000005176 gastrointestinal motility Effects 0.000 abstract 3
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 206010000087 Abdominal pain upper Diseases 0.000 abstract 1
- 208000002881 Colic Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000009546 Neurogenic bowel Diseases 0.000 abstract 1
- 208000005392 Spasm Diseases 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 210000001072 colon Anatomy 0.000 abstract 1
- 208000007784 diverticulitis Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000001848 dysentery Diseases 0.000 abstract 1
- 208000010227 enterocolitis Diseases 0.000 abstract 1
- 210000002429 large intestine Anatomy 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 210000000813 small intestine Anatomy 0.000 abstract 1
- 230000001148 spastic effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- VSRBKQFNFZQRBM-UHFFFAOYSA-N tuaminoheptane Chemical compound CCCCCC(C)N VSRBKQFNFZQRBM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45452703P | 2003-03-14 | 2003-03-14 | |
| PCT/IB2004/001134 WO2004080446A1 (en) | 2003-03-14 | 2004-03-12 | Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ542260A true NZ542260A (en) | 2009-03-31 |
Family
ID=32990912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ542260A NZ542260A (en) | 2003-03-14 | 2004-03-12 | Treatment of intestinal conditions with mecamylamine |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20040209961A1 (https=) |
| EP (1) | EP1603544B1 (https=) |
| JP (1) | JP2006520379A (https=) |
| AT (1) | ATE375152T1 (https=) |
| AU (1) | AU2004218899A1 (https=) |
| CA (1) | CA2518385A1 (https=) |
| CY (1) | CY1108042T1 (https=) |
| DE (1) | DE602004009414T2 (https=) |
| DK (1) | DK1603544T3 (https=) |
| ES (1) | ES2294480T3 (https=) |
| MX (1) | MXPA05009640A (https=) |
| NO (1) | NO20054670L (https=) |
| NZ (1) | NZ542260A (https=) |
| PL (1) | PL1603544T3 (https=) |
| PT (1) | PT1603544E (https=) |
| WO (1) | WO2004080446A1 (https=) |
| ZA (1) | ZA200507159B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070224284A1 (en) * | 2004-03-12 | 2007-09-27 | John Devane | Methods and compositions comprising at least one alpha3 beta4 nAChR antagonist or pharmaceutically acceptable salt thereof |
| US20060182819A1 (en) * | 2005-02-17 | 2006-08-17 | Ough Yon D | Soap scent patch and treatment for muscle spasm and pain |
| US20060182818A1 (en) * | 2005-02-17 | 2006-08-17 | Ough Yon D | Transdermal patch and treatment for pain and discomfort |
| US20070108228A1 (en) * | 2005-11-15 | 2007-05-17 | Willam Kleyne | Method and apparatus for flushing eyes and skin |
| US20080207766A1 (en) * | 2007-02-27 | 2008-08-28 | Agi Therapeutics Research Ltd. | Methods and compositions for treating at least one upper gastrointestinal symptom |
| WO2009143403A1 (en) * | 2008-05-23 | 2009-11-26 | Targacept, Inc. | Combination therapy for the management hypertension |
| NZ598534A (en) * | 2009-09-29 | 2014-03-28 | Novartis Ag | Dosage regimen of an s1p receptor modulator |
| US8529914B2 (en) | 2010-06-28 | 2013-09-10 | Richard C. Fuisz | Bioactive dose having containing a material for modulating pH of a bodily fluid to help or hinder absorption of a bioactive |
| EP3439676B1 (en) | 2016-04-04 | 2021-06-09 | Omeza LLC | Fish oil topical composition |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6034079A (en) * | 1997-08-11 | 2000-03-07 | University Of South Florida | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders |
| JP2001518520A (ja) * | 1997-10-03 | 2001-10-16 | キャリー メディカル コーポレイション | ニコチンレセプターアンタゴニストおよび抗抑うつ薬または抗不安薬を含有するニコチン嗜癖を治療する組成物 |
| AR016212A1 (es) * | 1998-04-28 | 2001-06-20 | Astra Ab | Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas |
| US6121289A (en) * | 1998-10-09 | 2000-09-19 | Theramax, Inc. | Method for enhanced brain delivery of nicotinic antagonist |
| NZ525878A (en) * | 1998-12-07 | 2004-12-24 | Elan Pharma Int Ltd | A method of treating nicotine dependance with mecamylamine |
| US6734215B2 (en) * | 1998-12-16 | 2004-05-11 | University Of South Florida | Exo-S-mecamylamine formulation and use in treatment |
| PT1634498E (pt) * | 1998-12-16 | 2008-10-28 | Univ South Florida | Formulação de exo-s-mecamilamina |
| AU3104301A (en) * | 2000-01-20 | 2001-07-31 | Noven Pharmaceuticals, Inc. | Compositions and methods to effect the release profile in the transdermal administration of active agents |
| US6780871B2 (en) * | 2001-01-29 | 2004-08-24 | Albany Medical College | Methods and compositions for treating addiction disorders |
-
2004
- 2004-03-12 ES ES04720110T patent/ES2294480T3/es not_active Expired - Lifetime
- 2004-03-12 CA CA002518385A patent/CA2518385A1/en not_active Abandoned
- 2004-03-12 PT PT04720110T patent/PT1603544E/pt unknown
- 2004-03-12 EP EP04720110A patent/EP1603544B1/en not_active Expired - Lifetime
- 2004-03-12 AU AU2004218899A patent/AU2004218899A1/en not_active Abandoned
- 2004-03-12 MX MXPA05009640A patent/MXPA05009640A/es active IP Right Grant
- 2004-03-12 US US10/798,421 patent/US20040209961A1/en not_active Abandoned
- 2004-03-12 PL PL04720110T patent/PL1603544T3/pl unknown
- 2004-03-12 NZ NZ542260A patent/NZ542260A/xx unknown
- 2004-03-12 DE DE602004009414T patent/DE602004009414T2/de not_active Expired - Lifetime
- 2004-03-12 DK DK04720110T patent/DK1603544T3/da active
- 2004-03-12 WO PCT/IB2004/001134 patent/WO2004080446A1/en not_active Ceased
- 2004-03-12 AT AT04720110T patent/ATE375152T1/de not_active IP Right Cessation
- 2004-03-12 JP JP2006506469A patent/JP2006520379A/ja active Pending
-
2005
- 2005-09-06 ZA ZA200507159A patent/ZA200507159B/en unknown
- 2005-10-11 NO NO20054670A patent/NO20054670L/no not_active Application Discontinuation
-
2008
- 2008-01-09 CY CY20081100029T patent/CY1108042T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE602004009414T2 (de) | 2008-07-24 |
| ZA200507159B (en) | 2008-03-26 |
| PL1603544T3 (pl) | 2008-03-31 |
| PT1603544E (pt) | 2008-01-22 |
| EP1603544B1 (en) | 2007-10-10 |
| NO20054670L (no) | 2005-12-13 |
| CY1108042T1 (el) | 2013-09-04 |
| WO2004080446A1 (en) | 2004-09-23 |
| ES2294480T3 (es) | 2008-04-01 |
| CA2518385A1 (en) | 2004-09-23 |
| DK1603544T3 (da) | 2008-01-14 |
| AU2004218899A1 (en) | 2004-09-23 |
| ATE375152T1 (de) | 2007-10-15 |
| DE602004009414D1 (de) | 2007-11-22 |
| EP1603544A1 (en) | 2005-12-14 |
| MXPA05009640A (es) | 2005-10-26 |
| US20040209961A1 (en) | 2004-10-21 |
| JP2006520379A (ja) | 2006-09-07 |
| WO2004080446B1 (en) | 2004-12-09 |
| NO20054670D0 (no) | 2005-10-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005072113A3 (en) | Compositions and methods of treatment for inflammatory diseases | |
| NZ542260A (en) | Treatment of intestinal conditions with mecamylamine | |
| EP2280085A3 (en) | Compositions and methods for diagnosing colon disorders | |
| Ikee et al. | Constipation in chronic kidney disease: it is time to reconsider | |
| MA31905B1 (fr) | DERIVES D'AMIDES DE L'ACIDE 6,7-DIHYDRO-5H-IMIDAZO[1,2-alpha] IMIDAZOLE-3-CARBOXYLIQUE | |
| EP1723083A4 (en) | REMOVAL OF CARBON, NITROGEN AND PHOSPHORUS FROM WATER USING SWIVEL LAYERS | |
| WO2002066511A3 (en) | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders | |
| EP2821085A3 (en) | RNA interference for the treatment of gain-of-function disorders | |
| UA84402C2 (ru) | Применение монооксида углерода для лечения воспаления почек | |
| Clemens et al. | Association between pain episodes and high amplitude propagated pressure waves in patients with irritable bowel syndrome | |
| BRPI0504758A (pt) | miméticos de interleucina-8 e métodos para usá-los em prevenção, tratamento, diagnóstico, e melhora dos sintomas de uma doença | |
| WO2007116395A3 (en) | Antisense oligonucleotides against acetylcholinesterase for treating inflammatory diseases | |
| Maneerattanaporn et al. | Sleep disorders and gastrointestinal symptoms: chicken, egg or vicious cycle? | |
| Rispo et al. | Lower prevalence of diverticulosis in patients with ulcerative colitis | |
| TR200102583T2 (tr) | Alt idrar yolları semptomlarının tedavisine yönelik farmasötik bileşim. | |
| RU2011116400A (ru) | Средство для предотвращения и/или лечения функционального расстройства желудочно-кишечного тракта | |
| WO2006006152A3 (en) | Treatment of disorders and diseases of the colon | |
| BRPI0415192A (pt) | processo para purificação de um composto | |
| WO2004085677A3 (en) | Novel markers for inflammatory bowel disease | |
| Mekky et al. | THE CORRELATION BETWEEN SPIRITUALITY, COGNITIVE FUNCTIONS AND COGNITIVE FLEXIBILITY IN RELAPSING REMITTING MULTIPLE SCLEROSIS PATIENTS | |
| Campbell et al. | Regional genetic architecture of the corpus callosum and its overlap with psychiatric and substance use phenotypes | |
| Ting et al. | Mesangiocapillary (membranoproliferative) glomerulonephritis and rheumatoid arthritis | |
| JP2010507650A5 (https=) | ||
| Nakagawa et al. | Irsogladine maleate prevents colitis in interleukin-10 gene-deficient mice by reducing interleukin-12 and-23 production | |
| van der Veek et al. | Tumor necrosis factor-alpha and interleukin 10 gene polymorphisms in irritable bowel syndrome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |